BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Policy

  Sernova Receives U.S. FDA IND Allowance to Initiate a U.S. Clinical Trial of its Cell Pouch for the Treatment of Type 1 Diabetes

  Sernova plans to initiate the new clinical trial under this US IND to investigate the Cell Pouch for tT1D in individuals with hypoglycemia unawareness.

  December 11, 2017

   · 

  6 min read
• Drug Development

  BeiGene Presents Initial Phase Ib Data for BTK Inhibitor Zanubrutinib (BGB-3111) Combined With PD-1 Antibody Tislelizumab (BGB-A317) at the 59th American Society of Hematology Annual Meeting

  The initial dose escalation data suggest that the combination of zanubrutinib and tislelizumab had a manageable toxicity profile and anti-tumor activity in patients with B-cell malignancies.

  December 11, 2017

   · 

  7 min read
• Drug Development

  GBT Announces New Phase IIa Data at ASH for Voxelotor in Adolescents With Sickle Cell Disease (SCD)

  The HOPE-KIDS 1 Study is an ongoing open-label, single- and multiple-dose study evaluating the safety, tolerability, pharmacokinetics and exploratory treatment effect of voxelotor in a pediatric population with SCD.

  December 11, 2017

   · 

  8 min read
• Drug Development

  Spark Therapeutics and Pfizer Announce Longer-term Preliminary Data Showing Consistent and Sustained Factor IX Levels in Hemophilia B at 59th American Society of Hematology (ASH) Annual Meeting and Exposition

  December 11, 2017

   · 

  10 min read
• Drug Development

  GBT Announces Presentation of Six Studies at ASH Supporting Voxelotor Sickle Cell Disease (SCD) Program

  The data were presented in oral and poster sessions during the 59th American Society of Hematology (ASH) Annual Meeting & Exposition at the Georgia World Congress Center in Atlanta.

  December 11, 2017

   · 

  12 min read
• Drug Development

  TG Therapeutics Announces Preclinical & Clinical Data Presentations at the 59th American Society of Hematology Annual Meeting

  The following summarizes the highlights from each poster presented at the ASH 2017 meeting.

  December 11, 2017

   · 

  9 min read
• Drug Development

  Anavex Life Sciences Reports Fiscal 2017 Financial Results And Provides Update On Therapeutic Programs

  The Company also provided an update on its most advanced programs for ANAVEX®2-73 for the treatment of Rett syndrome (RTT).

  December 11, 2017

   · 

  9 min read
• Biotech Bay

  Genomic Health Presents New Data Demonstrating Value of Oncotype DX to Optimize Breast Cancer Outcomes and Reduce Treatment Burden Throughout Disease Continuum

  The analysis demonstrated that Recurrence Score results significantly predicted the likelihood of clinical response to neoadjuvant therapy.

  December 11, 2017

   · 

  10 min read
• Pharm Country

  German Federal Ministry of Education and Research to Fund the CytoSorb Endocarditis REMOVE Trial

  The study is expected to begin in early 2018.

  December 11, 2017

   · 

  6 min read
• Business

  Boehringer Ingelheim Marks Great Progress in Immuno-Oncology Research Partnerships in 2017

  External partnerships complement Boehringer Ingelheim’s two-pronged research strategy - investigating both cancer cell-directed therapies and immune cell-directed therapies.

  December 11, 2017

   · 

  5 min read